China still has ‘catching up to do’ to become biotech powerhouse, JPMorgan says
A lag in foundational research and looming geopolitical risks will weigh on China’s bid to build a world-class biotechnology innovation ecosystem, even as the sector’s overseas momentum remains strong, according to JPMorgan. “In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research,” said Yang Huang, head of China healthcare…
We haven't written up this one. South China Morning Post has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.